Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog

Advertising today archive

2005 PWToday Stories

Recipharm enables PledPharma to re-start myocardial infection trial following approval from the Swedish Medical Products Agency

09 Jan 12

New Mangafodipir trial product to be manufactured by Recipharm

Recipharm, the international contract pharmaceutical development and manufacturing organisation, express satisfaction at the news that PledPharma’s new mangafodipir clinical trial product which is supplied by Recipharm’s pharmaceutical development group has been approved by the Swedish Medical Products Agency. Earlier this year, patient recruitment on the MANAMI study ceased - due to a lack of clinical trial substance. Following an approach by PledPharma, Recipharm has worked together with PledPharma to enure an approval from the regulatory body allowing the continuation of the MANAMI study.

The decision is highly significant for myocardial infarction (heart attack) patients, enabling PledPharma to continue its promising MANAMI study into the ability of mangafodipir to improve treatment outcomes during angioplasty.

Read full story here.

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.